Journal
NATURE CHEMICAL BIOLOGY
Volume 10, Issue 4, Pages 298-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/NCHEMBIO.1455
Keywords
-
Categories
Funding
- US National Institutes of Health (NIH) [R03DA030552]
- National Center for Advancing Translational Sciences
- NIH [R01GM097468, R01DK082779, T32GM008550]
- Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical Research [U54MH084681]
Ask authors/readers for more resources
Protein ubiquitination and deubiquitination are central to the control of a large number of cellular pathways and signaling networks in eukaryotes. Although the essential roles of ubiquitination have been established in the eukaryotic DNA damage response, the deubiquitination process remains poorly defined. Chemical probes that perturb the activity of deubiquitinases (DUBs) are needed to characterize the cellular function of deubiquitination. Here we report ML323 (2), a highly potent inhibitor of the USP1-UAF1 deubiquitinase complex with excellent selectivity against human DUBs, deSUMOylase, deneddylase and unrelated proteases. Using ML323, we interrogated deubiquitination in the cellular response to UV-and cisplatin-induced DNA damage and revealed new insights into the requirement of deubiquitination in the DNA translesion synthesis and Fanconi anemia pathways. Moreover, ML323 potentiates cisplatin cytotoxicity in non-small cell lung cancer and osteosarcoma cells. Our findings point to USP1-UAF1 as a key regulator of the DNA damage response and a target for overcoming resistance to the platinum-based anticancer drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available